抗逆转录病毒药物对人类免疫缺陷病毒感染者糖脂代谢及体重影响的研究进展  

Research progress on the effects of anti-retroviral agents on glucose and lipid metabolism and body weight in patients with human immunodeficiency virus infection

作　　者：肖然[1] 杜小莉[1] 李太生[2] Xiao Ran;Du Xiaoli;Li Taisheng(Department of Pharmacy,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Infectious Diseases,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院药剂科,北京100730 [2]中国医学科学院北京协和医学院北京协和医院感染科,北京100730

出　　处：《药物不良反应杂志》2025年第1期36-43,共8页Adverse Drug Reactions Journal

基　　金：中央高水平医院临床科研专项(2022-PUMCH-B-058)。

摘　　要：抗逆转录病毒治疗(ART)显著提高了人类免疫缺陷病毒(HIV)感染者的生存率和生活质量。随着患者生存期的延长,药物导致患者血糖升高、血脂异常和体重增加等新的健康问题日益突出。不同的抗逆转录病毒药物对血糖、血脂及脂肪组织的影响不同。本文综述了近年来核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂、蛋白酶抑制剂、整合酶抑制剂对HIV感染者血糖、血脂代谢及体重影响的研究进展,并提出相应管控建议。Antiretroviral therapy(ART)significantly improves the survival rate and quality of life of patients with human immunodeficiency virus(HIV)infection.However,with the extension of patients′survival time,drug-induced new health problems such as blood glucose increase,dyslipidemia,and weight gain are becoming prominent.Different antiretroviral agents have different effects on blood glucose,blood lipid and adipose tissue.This paper reviews the research progress on effects of nucleoside reverse transcriptase inhibitors,non-nucleoside reverse transcriptase inhibitors,protease inhibitors,integrase inhibitors on blood glucose,lipid metabolism and body weight in HIV-infected people in recent years,and puts forward corresponding control suggestions.

关 键 词：抗逆转录病毒药物 抗HIV药 糖代谢障碍 脂代谢障碍 体重 人类免疫缺陷病毒 

分 类 号：R978.7[医药卫生—药品]